Sonic Healthcare Limited (SHL) Earnings Dates, Call Summary & Reports

Q: When does Sonic Healthcare Limited (AU:SHL) report earnings?

Sonic Healthcare Limited (AU:SHL) is schdueled to report earning on Aug 26, 2026, TBA (Confirmed).

Q: What is Sonic Healthcare Limited (AU:SHL) earnings time?

Sonic Healthcare Limited (AU:SHL) earnings time is at Aug 26, 2026, TBA (Confirmed).

Q: Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

Q: What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

Q: What is the P/E ratio of Sonic Healthcare Limited stock?

The P/E ratio of {name} is N/A.

Q: What is AU:SHL EPS forecast?

AU:SHL EPS forecast for the fiscal quarter 2026 (Q4) is 0.66.

Compare

168 Followers

Earnings Data

Report Date

Aug 26, 2026

TBA (Confirmed)

Period Ending

2026 (Q4)

Consensus EPS Forecast

0.66

Last Year’s EPS

0.58

Same Quarter Last Year

Analyst Consensus

Hold

Based on 10 Analysts Ratings

Earnings Call Summary

Q2 2026

Earnings Call Date:Feb 18, 2026|

% Change Since:

Earnings Call Sentiment|Positive

The call presents a broadly positive operational and financial position — solid H1 results, maintained full-year EBITDA guidance, margin expansion (+30 bps), diversified organic growth across key markets (Germany, Australia, UK, Radiology) and progress on acquisitions, digital pathology and capital management initiatives (dividend increase, sale-and-leaseback program). Headwinds are meaningful but generally manageable: U.S. margin pressure and restructuring, slower revenue-collection benefits pushed into FY2027, working-capital distortion from a Change Healthcare cyber incident, higher net debt from acquisitions/property spending, FX uncertainty and pending Australian wage decisions. Management emphasizes operating leverage, synergy capture and disciplined capital allocation to address these challenges.

Company Guidance

Management maintained full‑year adjusted EBITDA guidance of AUD 1.87–1.95 billion on a constant‑currency basis, after reporting H1 revenue of AUD 5.445 billion, H1 EBITDA of AUD 907 million, H1 net profit of AUD 262 million and EPS of AUD 0.531; group organic growth was ~5% with adjusted EBITDA margins up 30 basis points year‑on‑year. They tightened below‑the‑line guidance to depreciation of AUD 770–780 million (constant currency), an interest‑expense increase of about 15% year‑on‑year (constant currency) and an effective tax rate of 27%; guidance excludes property sale gains, assumes only completed acquisitions and prevailing interest rates. Capital management metrics and priorities include maintaining an investment‑grade balance sheet (debt cover ratio ~2.5x), available headroom of ~AUD 1.0 billion before the interim dividend, a progressive interim dividend of AUD 0.45 (up 2.3%, 60% franked, record 5 Mar, pay 19 Mar) and a medium‑term dividend payout target of 70–80% of net profit, with potential sale‑and‑leaseback proceeds earmarked for share buybacks; management also flagged an FX tailwind for the full year that will be smaller than H1 and noted H1 acquisition costs of AUD 8 million.

Strong H1 Financial Results

Revenue of $5.445 billion, EBITDA of $907 million and net profit of $262 million for H1 FY2026; EPS AUD 0.531. Management maintained full-year adjusted EBITDA guidance of $1.87bn–$1.95bn (constant currency).

Organic Revenue Growth

Group organic growth of 5% in H1 FY2026, with particularly strong contributions from Australian Pathology (organic +5%) and other divisions.

Regional Outperformance and High-Growth Markets

Germany delivered 40% revenue growth on a constant currency basis (organic +5%); United Kingdom organic growth +24% driven by Hertfordshire & West Essex contract; Radiology organic revenue growth +7%; Sonic Clinical Services revenue +5% with EBITDA growth +20% (from a low base).

Margin Expansion and Operating Leverage

Adjusted EBITDA margins increased by ~30 basis points year-on-year (H1 2025 → H1 2026) and management highlights operating leverage and synergy realization across most businesses.

Acquisitions and Integration Progress

LADR (Germany) settled 1 July 2025 and integration across 16 workstreams is progressing to plan; Cairo Diagnostics and ThyroSeq included in an expanded Advanced Diagnostics division; >60% of dermatopathology volume now on proprietary PathologyWatch digital platform.

Capital Management and Balance Sheet Flexibility

Interim dividend increased by 2.3% to AUD 0.45 (60% franked); target medium-term payout ratio 70–80%. Debt cover ratio at 2.5x and available headroom ~US$1 billion before interim dividend. Sale-and-leaseback program initiated to unlock capital and fund potential on-market buybacks.

Reduced Depreciation Guidance and More Transparency Below EBITDA

Depreciation forecast lowered to $770m–$780m (constant currency). Management provided tighter below-EBITDA guidance (depreciation, interest and tax rate guidance at 27%).

Operational Wins and Productivity Initiatives

Major lab platform procurement completed delivering substantial savings; new hub labs (e.g., Watford, Melbourne Docklands) and automation investments underway; partnership with National Lung Cancer Screening Program boosting CT volumes.

Sonic Healthcare Limited (AU:SHL) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

AU:SHL Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 26, 2026	2026 (Q4)	0.66 / -	0.575	―	―	―
Feb 18, 2026	2026 (Q2)	0.53 / 0.50	0.492	1.63% (<+0.01)	―	―
Aug 20, 2025	2025 (Q4)	0.59 / 0.57	0.597	-3.69% (-0.02)	―	―
Feb 19, 2025	2025 (Q2)	0.51 / 0.49	0.426	15.49% (+0.07)	―	―
Aug 21, 2024	2024 (Q4)	0.60 / 0.60	0.678	-11.95% (-0.08)	―	―
Feb 19, 2024	2024 (Q2)	0.66 / 0.43	0.809	-47.34% (-0.38)	―	―
Aug 17, 2023	2023 (Q4)	0.73 / 0.68	1.32	-48.64% (-0.64)	―	―
Feb 15, 2023	2023 (Q2)	0.82 / 0.81	1.708	-52.63% (-0.90)	―	―
Aug 23, 2022	2022 (Q4)	1.11 / 1.32	1.339	-1.42% (-0.02)	―	―
Feb 20, 2022	2022 (Q2)	2.57 / 1.71	1.422	20.11% (+0.29)	―	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

AU:SHL Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Feb 18, 2026	AU$20.84	AU$22.89	+9.89%
Aug 20, 2025	AU$27.45	AU$23.92	-12.84%
Feb 19, 2025	AU$27.10	AU$26.36	-2.74%
Aug 21, 2024	AU$25.46	AU$25.67	+0.79%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Sonic Healthcare Limited (AU:SHL) report earnings?

Sonic Healthcare Limited (AU:SHL) is schdueled to report earning on Aug 26, 2026, TBA (Confirmed).

What is Sonic Healthcare Limited (AU:SHL) earnings time?

Sonic Healthcare Limited (AU:SHL) earnings time is at Aug 26, 2026, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is the P/E ratio of Sonic Healthcare Limited stock?

The P/E ratio of Sonic Healthcare Limited is N/A.

What is AU:SHL EPS forecast?

AU:SHL EPS forecast for the fiscal quarter 2026 (Q4) is 0.66.